| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ... Nature medicine 23 (6), 703-713, 2017 | 2991 | 2017 |
| Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial E Basch, AM Deal, MG Kris, HI Scher, CA Hudis, P Sabbatini, L Rogak, ... Journal of Clinical Oncology 34 (6), 557-565, 2016 | 2233 | 2016 |
| OncoKB: a precision oncology knowledge base D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ... JCO precision oncology 1, 1-16, 2017 | 2050 | 2017 |
| Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial ML Hensley, R Maki, E Venkatraman, G Geller, M Lovegren, ... Journal of Clinical Oncology 20 (12), 2824-2831, 2002 | 811 | 2002 |
| Risk-reducing salpingo-oophorectomy for the prevention of BRCA1-and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study ND Kauff, SM Domchek, TM Friebel, ME Robson, J Lee, JE Garber, ... Journal of clinical oncology 26 (8), 1331-1337, 2008 | 712 | 2008 |
| NCCN Practice Guidelines for Cancer-Related Fatigue. V Mock, A Atkinson, A Barsevick, D Cella, B Cimprich, C Cleeland, ... Oncology (Williston Park, NY) 14 (11A), 151-161, 2000 | 655 | 2000 |
| Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study … RL Coleman, MF Brady, TJ Herzog, P Sabbatini, DK Armstrong, JL Walker, ... The Lancet Oncology 18 (6), 779-791, 2017 | 616 | 2017 |
| A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies C Aghajanian, S Soignet, DS Dizon, CS Pien, J Adams, PJ Elliott, ... Clinical cancer research 8 (8), 2505-2511, 2002 | 615 | 2002 |
| Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach DS Chi, CC Franklin, DA Levine, F Akselrod, P Sabbatini, WR Jarnagin, ... Gynecologic oncology 94 (3), 650-654, 2004 | 381 | 2004 |
| Patient online self-reporting of toxicity symptoms during chemotherapy E Basch, D Artz, D Dulko, K Scher, P Sabbatini, M Hensley, N Mitra, ... Journal of clinIcal oncology 23 (15), 3552-3561, 2005 | 353 | 2005 |
| Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset DO Hardy, HI Scher, T Bogenreider, P Sabbatini, ZF Zhang, DM Nanus, ... The Journal of Clinical Endocrinology & Metabolism 81 (12), 4400-4405, 1996 | 330 | 1996 |
| Ovarian cancer, version 1.2016, NCCN clinical practice guidelines in oncology RJ Morgan, DK Armstrong, RD Alvarez, JN Bakkum-Gamez, K Behbakht, ... Journal of the National Comprehensive Cancer Network 14 (9), 1134-1163, 2016 | 329 | 2016 |
| Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients P Sabbatini, T Tsuji, L Ferran, E Ritter, C Sedrak, K Tuballes, ... Clinical cancer research 18 (23), 6497-6508, 2012 | 325 | 2012 |
| Secondary surgical cytoreduction for recurrent ovarian cancer RL Coleman, NM Spirtos, D Enserro, TJ Herzog, P Sabbatini, ... New England Journal of Medicine 381 (20), 1929-1939, 2019 | 304 | 2019 |
| Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer P Sabbatini, SM Larson, A Kremer, ZF Zhang, M Sun, H Yeung, ... Journal of clinical oncology 17 (3), 948-948, 1999 | 287 | 1999 |
| Adjuvant gemcitabine plus docetaxel for completely resected stages I–IV high grade uterine leiomyosarcoma: results of a prospective study ML Hensley, N Ishill, R Soslow, J Larkin, N Abu-Rustum, P Sabbatini, ... Gynecologic oncology 112 (3), 563-567, 2009 | 249 | 2009 |
| NCCN guidelines insights: Ovarian cancer, version 1.2019: Featured updates to the NCCN guidelines DK Armstrong, RD Alvarez, JN Bakkum-Gamez, L Barroilhet, K Behbakht, ... Journal of the National Comprehensive Cancer Network 17 (8), 896-909, 2019 | 241 | 2019 |
| Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II) S Reinartz, S Köhler, H Schlebusch, K Krista, P Giffels, K Renke, ... Clinical Cancer Research 10 (5), 1580-1587, 2004 | 197 | 2004 |
| Early detection and prognosis of ovarian cancer using serum YKL-40 J Dupont, MK Tanwar, HT Thaler, M Fleisher, N Kauff, ML Hensley, ... Journal of clinical oncology 22 (16), 3330-3339, 2004 | 196 | 2004 |
| Farletuzumab, a humanized monoclonal antibody against folate receptor α, in epithelial ovarian cancer: a phase I study JA Konner, KM Bell-McGuinn, P Sabbatini, ML Hensley, WP Tew, ... Clinical Cancer Research 16 (21), 5288-5295, 2010 | 188 | 2010 |
